New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:52 EDTORAN, SLB, SNYWestern companies may seek return to Iran as sanctions ease, WSJ says
Temporary sanctions relief hasn't yet translated into an economic turnaround in Iran, but a steady flow of executives in recent weeks signals that some companies that previously did business there, such as Schlumberger (SLB), Sanofi (SNY), and Orange (ORAN), may be interested in exploring a return, according to The Wall Street Journal. Reference Link
News For ORAN;SNY;SLB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 25, 2015
09:01 EDTSLBDomtar announces investment by Schlumberger in CelluForce
Subscribe for More Information
March 23, 2015
10:55 EDTSLBSchlumberger says global economy trend is slow but stead recovery intact
Subscribe for More Information
09:45 EDTSNYUBS to hold a field trip
Subscribe for More Information
09:37 EDTSLBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
07:27 EDTORANCityFibre claims BT takeover of EE is anticompetitive, The Telegraph says
CityFibre has filed a claim with British antitrust authorities alleging BTís (BT) GBP12.5B takeover of EE is anticompetitive, reports The Telegraph, citing statements by CityFibre CEO Greg Mesch. BT has claimed that it will immediately cut costs if the takeover proposal succeeds, and CityFibre believes its earlier contract with EE to expand its fibre-optic network will be "effectively neutered." EE is a joint venture by Orange (ORAN) and Deutsche Telekom (DTEGY). Reference Link
07:16 EDTSLBHoward Weil to hold a conference
Subscribe for More Information
March 20, 2015
07:31 EDTSLBOneSubsea delivers first subsea multiphase compressor to Statoil
OneSubsea, a Cameron (CAM) and Schlumberger (SLB) company, has delivered the world's first subsea Multiphase Compressor to Statoil (STO) for the Gullfaks South field in the North Sea. The subsea multiphase compressor enables boosting of unprocessed wet gas production fluids, while eliminating the need for an upstream separation facility or an anti-surge system, making it the industry's only true wet gas compressor. It is expected to increase the recovery rate for the Gullfaks South Brent reservoir by 22M barrels of oil equivalent.
07:19 EDTSLBWhite House expected to unveil fracking rules today, WSJ says
Subscribe for More Information
March 19, 2015
07:09 EDTSNYSanofi reports top-line results for Lyxumia for cardiovascular safety
Sanofi announced top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk population of adults with type 2 diabetes evaluating cardiovascular safety. The study showed that lixisenatide was non-inferior, although not superior, to placebo for cardiovascular safety. The results will be included in the U.S. New Drug Application of lixisenatide, which is on track to be resubmitted to the FDA in Q3. Lixisenatide is not approved in the U.S.
05:30 EDTSNYSanofi reports lixisenatide was non-inferior, though not superior to placebo
Subscribe for More Information
March 18, 2015
09:32 EDTSNYMannKind faces cash shortfall if $100M debt not settled, TheStreet says
Subscribe for More Information
March 17, 2015
10:00 EDTSNYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:02 EDTSNYSanofi says Shantha will provide up to 37M doses of Shan5
Sanofi Pasteur, the vaccines division of Sanofi, announced that its affiliate Shantha Biotechnics of Hyderabad, India has delivered the first 400,000 doses of its pediatric pentavalent vaccine Shan5 to support the immunization of children in the cities of Gwalior and Jabalpur, both in the state of Madhya Pradesh, India. In December 2014, following a two-year international tender, Shantha was awarded to supply global health organizations with a total of 37M doses of Shan5 in 2015 and 2016, in a ten-dose vial presentation. This tender provides the basis upon which purchase orders will be made for specific vaccine deliveries throughout the period, the company said.
07:43 EDTSNYSanofi upgraded to Outperform on abating concerns at Leerink
Leerink upgraded Sanofi to Outperform from Market Perform saying key concerns around the lack of a CEO, Toujeo positioning and guidance are either resolved or largely factored into expectations. The firm believes the company's currency risk is hedged over time and that its multibillion dollar PCSK9 and dupilumab therapy assumptions have further upside potential. It raised its price target for shares to EUR 106 from EUR 85.
06:10 EDTORANOrange SA sees 2018 revenues higher than 2014 revenues
On the financial side, the objectives for the Group are as follows: 2018 revenues will be higher than 2014 revenues. Restated EBITDA in 2018 will be higher than restated EBITDA in 2014, with a low point in 2015 of between 11.9 and 12.1 billion euros, in line with the Groupís previously stated objective. The Group will maintain a healthy financial balance sheet, with a restated net debt to EBITDA ratio of 2x over the medium term. Concerning the dividend, the Group will maintain a minimum of 60 euro-cents per year over the period 2015-2018, without excluding the possibility of an increase depending on restated EBITDA performance.
06:10 EDTORANOrange SA to invest over EUR15B in networks from 2015-2018
Subscribe for More Information
05:40 EDTSNYSanofi upgraded to Outperform from Market Perform at Leerink
March 16, 2015
08:23 EDTSNYPCSK9 data continues to impress, says Leerink
Subscribe for More Information
07:16 EDTSNYRegeneron Sanofi dupilumab drug can generate $6B+ in revenue, says Bernstein
Bernstein believes that dupilumab, a drug made by Regeneron and Sanofi, has shown strong efficacy in patients with severe atopic dermatitis. The firm notes that the drug is currently in pivotal trials involving patients with severe levels of other common diseases. The firm thinks the drug can generate $1.5B of revenue by 2018 and $3.8B by 2020. Bernstein keeps a $500 price target and Outperform rating on Regeneron.
06:40 EDTSNYPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use